All In Biotech

Drug Trial Radar · NCT00596752

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV

Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV)

Last checked: Nov 19, 2026Latest source record: Apr 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

840

Actual

Start

Mar 2004

Primary completion

May 2013

Study completion Jul 2013

Sponsor

Lead sponsor
UCB BIOSCIENCES GmbHUCB
Sponsor type
Industry
Collaborators
Aptiv Solutions
First posted
Jan 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to confirmatorily show a superior effect of Alprostadil compared to placebo on the rate of complete healing of ischemic necroses and ulcerations as well as on the frequency and height of major amputations in patients suffering from PAOD stage IV.

Conditions

  • Peripheral Arterial Occlusive Disease

Interventions

  • AlprostadilDrug

    * Active Substance: Prostaglandin E1 * Pharmaceutical Form: solution for infusion * Concentration: 40 μg b.d. * Route of Administration: intravenous infusion

  • PlaceboOther

    * Active Substance: Lactose * Pharmaceutical Form: solution for infusion * Concentration: 40 μg b.d. * Route of Administration: intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug TreatmentTime frame: At 12 weeks after the end of study drug treatment
  2. Occurrence of Major Amputations at 24 Weeks After the End of Study Drug TreatmentTime frame: At 24 weeks after the end of study drug treatment

Locations

78 sites in 6 countries. Site status is shown where the registry gives one.

  • 404

    Pilsen, Czechia

  • 414

    Ústí nad Labem, Czechia

  • 1

    Karlsbad, Germany

  • 502

    Aguascalientes, Mexico

  • 505

    Mérida, Mexico

  • 501

    Querétaro, Mexico

  • 306

    Bydgoszcz, Poland

  • 321

    Gmina Końskie, Poland

  • 320

    Krakow, Poland

  • 314

    Lublin, Poland

  • 315

    Lublin, Poland

  • 316

    Poznan, Poland

  • 317

    Poznan, Poland

  • 301

    Szczecin, Poland

  • 304

    Szczecin, Poland

  • 307

    Warsaw, Poland

  • 308

    Warsaw, Poland

  • 309

    Warsaw, Poland

  • 318

    Warsaw, Poland

  • 319

    Warsaw, Poland

  • 312

    Wroclaw, Poland

  • 322

    Zamość, Poland

  • 246

    Barnaul, Russia

  • 205

    Chelyabinsk, Russia

  • 244

    Chelyabinsk, Russia

  • 228

    Irkutsk, Russia

  • 242

    Kazan', Russia

  • 227

    Kemerovo, Russia

  • 201

    Moscow, Russia

  • 202

    Moscow, Russia

  • 203

    Moscow, Russia

  • 209

    Moscow, Russia

  • 219

    Moscow, Russia

  • 220

    Moscow, Russia

  • 230

    Moscow, Russia

  • 248

    Moscow, Russia

  • 231

    Novosibirsk, Russia

  • 232

    Novosibirsk, Russia

  • 222

    Omsk, Russia

  • 217

    Petrozavodsk, Russia

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.